Overview

Molecular Subtype-Guided R-CHOP-MTXZanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

Evaluate the Efficacy and Safety of R-CHOP-MTXZanubrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Central Nervous System Involvement, and Explore the Efficacy Indicators of CSF-ctDNA.

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University